2'-FluorodDAP is rapidly converted to 2'-FluorodGuo, such that no prodrug can be detected in the plasma. Monitoring for clinical signs of infection, that is, inflammatory cell counts and determination of pyrexia, was carried out as described previously, as were virus titrations in nasal washes and lung samples (7, 8, 11, 12) . Virus titers were assayed by the allantoin-on-shell (egg-bit) or egg techniques (7, 8) or in Madin-Darby canine kidney (MDCK) cells (6) .
To estimate immune protection, animals were challenged intranasally under ether anesthesia with 106 50% egg infective doses (EID50s) of clone 7a 4 weeks after primary virus inoculation, and the level of protection was assessed as described previously (4) .
Effect against influenza A virus reassortant clone 7a. Initial studies in ferrets were designed on the basis of previous studies in mice (9, 10) to determine the minimum number of doses required to limit infection. Ferrets were inoculated with 106 EID50s of clone 7a and were divided into groups of four which were treated intraperitoneally with three doses of 40 mg of compound 2'-FluorodGuo per kg at 1, 8 , and 24 h post-virus exposure, two doses at 1 and 24 h post-virus exposure, and 1 dose at 1 h post-virus exposure. Treated ferrets were then compared with untreated virus-inoculated controls. Virus titers in nasal washes and lungs, pyrexia, and the nasal inflammatory response were monitored at intervals after infection. Data from the single-dose study are plotted in Fig. 1 , and the results calculated as mean level of virus in nasal washes and lungs, and cell and fever indices (determined from areas under individual curves) are shown for all dosing regimes in Table 1 .
In untreated animals ( Fig. 1) , virus peaked at 30 h (10-55 50% egg-bit infective doses [EBID50s]/ml) and then declined rapidly, with a second small peak of virus shedding occurring 96 h postinoculation (p.i.) (1025 EBID50s/ml) ( Fig. lA-a) . In contrast, in animals treated with one dose of 40 mg of 2'-FluorodGuo per kg at 1 h post-virus exposure, no initial virus peak was detectable but a small peak occurred at 60 h post-virus exposure; this small peak was about 200-fold less (1035 EBID50s/ml) than the peak in the untreated virusinoculated animals ( Fig. lA-a) . Similar Constitutional signs represented by febrile responses were also suppressed in treated, virus-inoculated animals. In untreated, inoculated animals, the febrile response lasted approximately 30 h, from 30 to 60 h p.i., with a peak mean temperature rise of 2.3°C (Fig. lA-b tory cells in nasal washes, were also considerably reduced (Fig.  lA-c) . In untreated, virus-inoculated animals, the inflammatory cellular response started at about 24 h p.i., reached a maximum of 10' cells at 54 h after inoculation, and remained approximately 100-fold above preinfection levels up to 168 h p.i. (Fig. lA-c) . Virus-inoculated animals treated with three, two, or one dose of 2'-FluorodGuo showed a significantly reduced response ( Fig. lA-c The levels of the compound in plasma for six individual virus-inoculated ferrets at 15 min after injection of the compound ranged from 19.0 to 76.5 ,uM (mean, 43.2 ± 9.1 ,uM), which is well above the 50% inhibitory concentration of 6.9 ,uM 2'-FluorodGuo for clone 7a as determined in MDCK cells (9) .
Despite the reduced level of replication in both the upper and lower respiratory tracts of the virus-inoculated treated animals, the hemagglutination-inhibition antibody titers determined by standard methods (2) were similar to those in controls (mean, 560 ± 80 in comparison with 240 ± 80, 560 + 80, and 480 ± 92 in animals treated with three, two, or one dose, respectively), and animals were protected against subsequent challenge.
From this study it was found that one dose given 1 h p.i. was sufficient to limit virus replication and inflammation in the upper respiratory tract and eliminate fever. Therefore, in subsequent studies, single-dose treatment regimens were used.
Effect of time of dosing. To determine the latest that the compound could be given but still control the infection, groups of virus-inoculated ferrets were injected with 40 mg of the prodrug 2'-FluorodDAP per kg at 4, 12, or 24 h post-virus exposure. Although previous work with mice indicated that the prodrug and 2'-FluorodGuo were interchangeable, a group of virus-inoculated ferrets was also injected with 40 mg of 2'-FluorodGuo per kg at 4 h post-virus exposure for comparison.
As described above, animals treated with 2'-FluorodGuo at 1 h post-virus exposure shed only low levels of virus, and both peak virus titers and total virus shed (virus index) were significantly reduced (P < 0.001) in comparison with those values for untreated controls (Table 2) . Virus levels were also significantly reduced when compound, both 2'-FluorodDAP and 2'-FluorodGuo, was given at 4 h post-virus exposure, but 2'-FluorodDAP was less effective when it was given at 12 h post-virus exposure, although virus levels were still significantly reduced (P < 0.01), and it was too late to influence the course of the infection when it was given at 24 h post-virus exposure ( Table 2 ). The effects on the nasal inflammatory cell response were similar to those on nasal virus levels, but fever was observed in all groups given compound later than 1 h, and in most cases this fever was not significantly less than that in control animals ( Table 2) . Considering the high level of virus challenge (106 EID50s) required to produce consistent infection in ferrets, these results are encouraging and indicate that these inhibitors have considerable therapeutic potential. In humans 0.6 to 50% tissue culture infective doses 3.0 are sufficient for infection (1) .
Effect of dose. To ascertain the minimum effective dose, groups of infected ferrets were inoculated with single doses of 20, 10, or 5 mg of 2'-FluorodDAP per kg at 1 h post-virus exposure. Control virus-inoculated, untreated animals showed responses similar to those in the animals in the experiments described above, and all three dose levels significantly reduced virus replication, nasal inflammatory responses, and fever (Table 3) . While the magnitudes of these responses did not differ significantly from those observed in ferrets treated with 40 mg/kg, virus was detectable over longer periods of time as the dose of compound was reduced.
Levels of 2'-FluorodGuo in plasma were 5.1 and 8.2, 16.9 and 18.4, and 40.8 and 42.4 p.M, respectively, for plasma from each of two virus-inoculated animals taken 15 min after injection with doses of 5, 10, and 20 mg of compound per kg.
Effect against influenza virus B/Singapore/222/79. To determine whether 2'-FluorodDAP was effective against influenza B virus, four animals were inoculated with 106 EID50s of B/ Singapore/222/79, and another group of four inoculated ferrets was treated with the compound 1 h later. Virus-inoculated, untreated animals started shedding virus within 24 h of inoculation, which peaked at 105 PFU/ml at 48 h p.i. but which remained at relatively high levels (between 103.0 and 104.0 PFU/ml) until 104 h p.i., when the levels declined rapidly (Fig.  lB-a) . Virus levels in treated, virus-inoculated animals were considerably reduced initially but peaked at levels (104.8 PFU/ ml) similar to those in untreated animals at 78 h post-virus exposure before declining (Fig. lB-a) ; the overall virus index for treated animals was significantly reduced in comparison with those for untreated animals (P < 0.01). Fever and nasal inflammation were also significantly reduced (Fig. lB-b and B-c). However, the efficacy of 2'-FluorodDAP was not as great against influenza B virus as it was against influenza A virus, despite similar efficacy in cell culture (9) . This suggests that more than one dose is required to obtain an optimum effect against influenza B virus. Thus, in conclusion, 2'-FluorodGuo and 2'-FluorodDAP are effective against influenza A and B virus infections in ferrets by reducing viral replication, which significantly reduces respiratory and constitutional signs of infection.
